MX2021008510A - Derivados de tiazolopiridina como antagonistas del receptor de adenosina. - Google Patents

Derivados de tiazolopiridina como antagonistas del receptor de adenosina.

Info

Publication number
MX2021008510A
MX2021008510A MX2021008510A MX2021008510A MX2021008510A MX 2021008510 A MX2021008510 A MX 2021008510A MX 2021008510 A MX2021008510 A MX 2021008510A MX 2021008510 A MX2021008510 A MX 2021008510A MX 2021008510 A MX2021008510 A MX 2021008510A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
adenosine receptor
thiazolopyridine derivatives
thiazolopyridine
derivatives
Prior art date
Application number
MX2021008510A
Other languages
English (en)
Inventor
Kai Schiemann
Alejandro Crespo
Krauel Eva-Maria Tanzer
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2021008510A publication Critical patent/MX2021008510A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a derivados de tiazolopiridina que se incluyen en la fórmula general I, (ver Fórmula) y al uso de los compuestos de la presente invención para el tratamiento y/o la prevención de enfermedades y trastornos hiperproliferativos o infecciosos en mamíferos, especialmente humanos, y a composiciones farmacéuticas que contienen tal compuesto.
MX2021008510A 2019-01-22 2020-01-21 Derivados de tiazolopiridina como antagonistas del receptor de adenosina. MX2021008510A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19152961 2019-01-22
PCT/EP2020/051347 WO2020152132A1 (en) 2019-01-22 2020-01-21 Thiazolopyridine derivatives as adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
MX2021008510A true MX2021008510A (es) 2021-09-21

Family

ID=65199346

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008510A MX2021008510A (es) 2019-01-22 2020-01-21 Derivados de tiazolopiridina como antagonistas del receptor de adenosina.

Country Status (13)

Country Link
US (1) US20220119412A1 (es)
EP (1) EP3914600B1 (es)
JP (1) JP2022524914A (es)
KR (1) KR20210116572A (es)
CN (1) CN113939520A (es)
AR (1) AR117844A1 (es)
AU (1) AU2020211697A1 (es)
BR (1) BR112021014406A2 (es)
CA (1) CA3127284A1 (es)
IL (1) IL285024A (es)
MX (1) MX2021008510A (es)
SG (1) SG11202107858WA (es)
WO (1) WO2020152132A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117858723A (zh) 2021-06-07 2024-04-09 阿雷斯贸易股份有限公司 癌症的联合治疗
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024028273A1 (en) 2022-08-02 2024-02-08 Merck Patent Gmbh Novel crystalline forms of (s)-7-oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2h-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide and co-crystal forms thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125828A (en) 1972-08-04 1978-11-14 Med-El Inc. Method and apparatus for automated classification and analysis of cells
US4207554A (en) 1972-08-04 1980-06-10 Med-El Inc. Method and apparatus for automated classification and analysis of cells
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PL194689B1 (pl) 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ATE242775T1 (de) 1998-01-05 2003-06-15 Eisai Co Ltd Purinderivate und antagonisten des adenosin-a2- rezeptors, welche zur vorsorge oder heilung von diabetes dienen
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CA2376835C (en) 1999-07-02 2009-09-15 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
IL153278A0 (en) * 2000-06-21 2003-07-06 Hoffmann La Roche Benzothiazole derivatives
IL153325A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US6734179B2 (en) * 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
US8080554B2 (en) 2001-12-12 2011-12-20 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
EP1618108A2 (en) 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists
KR100859886B1 (ko) * 2003-05-19 2008-09-23 에프. 호프만-라 로슈 아게 아데노신 수용체 리간드로서의 벤조싸이아졸 유도체
KR20060058132A (ko) * 2003-09-19 2006-05-29 에프. 호프만-라 로슈 아게 아데노신 수용체 리간드로서의 싸이아졸로피리딘 유도체
US7054288B2 (en) * 2004-02-13 2006-05-30 Interdigital Technology Corporation Method and apparatus for providing fast detection of a high speed shared control channel
DE102004008908A1 (de) * 2004-02-24 2005-09-08 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH Ansteuerschaltung für Wandler
FR2867354A1 (fr) * 2004-03-09 2005-09-16 Joseph Vaillant Ferrure mecanique pour sabot, notamment pour cheval de sport
ATE457986T1 (de) 2004-07-22 2010-03-15 Hoffmann La Roche Benzothiazolderivate
ES2951809T3 (es) * 2017-05-17 2023-10-25 Arcus Biosciences Inc Derivados de quinazolina-pirazol para el tratamiento de trastornos relacionados con el cáncer
PT3661941T (pt) * 2017-08-01 2023-03-16 Merck Patent Gmbh Derivados tiazolopiridina como antagonistas do recetor de adenosina

Also Published As

Publication number Publication date
CA3127284A1 (en) 2020-07-30
EP3914600B1 (en) 2024-08-07
KR20210116572A (ko) 2021-09-27
AU2020211697A1 (en) 2021-09-09
CN113939520A (zh) 2022-01-14
EP3914600A1 (en) 2021-12-01
SG11202107858WA (en) 2021-08-30
AR117844A1 (es) 2021-09-01
IL285024A (en) 2021-09-30
BR112021014406A2 (pt) 2021-12-07
WO2020152132A1 (en) 2020-07-30
US20220119412A1 (en) 2022-04-21
JP2022524914A (ja) 2022-05-11

Similar Documents

Publication Publication Date Title
WO2020097537A3 (en) Fused ring compounds
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
TN2018000043A1 (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
ZA202001295B (en) Thiazolopyridine derivatives as adenosine receptor antagonists
PH12019501846A1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EA033343B1 (ru) Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
MX2021008510A (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina.
CR20220236A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
ZA202001780B (en) Bezimidazole derivatives as adenosine receptor antagonists
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
EP2578590A4 (en) ANTI-INFLAMMATORY COMPOUND WITH ANTI-HUMAN EFFECT AGAINST SEVERAL TYROSIN KINASES AND PHARMACEUTICAL COMPOSITION THEREWITH
AU2020288559A8 (en) Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2023009059A (es) Antagonistas de gpr84 y usos de estos.
SA521421098B1 (ar) -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين
PH12021550258A1 (en) Cdk8/19 inhibitors
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.